DESCRIPTION
THREE-COMPONENT MIXING APPARATUS AND THREE-COMPONENT MIXING
ADHESIVE KIT
Technical Field
[0001]
The present invention relates to a three-component mixing
apparatus and a three-component mixing adhesive kit suitable as
a mixing container of a three-component mixing adhesive agent used
in, for example, surgical procedure (or treatment) or dental
procedure (or treatment).
Background Art
[0002]
In surgical procedure, for instance, suturing generally
involves the use of suture thread. Suturing using suture thread,
which is performed by someone's hands for long hours, cannot
completely eliminate infection risk. In addition, since the
surgical procedure leaves clear mark over a wide range, some
surgical procedures have recently involved using adhesive agents
in combination or singly. Using the adhesive agents to suture
wound as described above can obviously reduce infection risk in
operation and further improve esthetics after operation.
SF-2655
2
[0003]
As the adhesive agent used in surgical procedure, two or
more kinds of components are often mixed and used. Conventionally,
such adhesive agents are used by introducing drugs in separate
containers in advance, and then detaching a cap of a first
component container and a cap of a second component container,
and moving one drug of one component container to the other
container. If a third drug is used, the third drug is generally
added to the container in which the drugs of two kinds have been
mixed. However, mixing three components as drugs in appropriate
amount uniformly is cumbersome and is required to be improved.
[0004]
An apparatus widespread for the mixing of a two-component
mixing adhesive agent is disclosed in Patent Literature 1: with
two components previously separately introduced in one syringe,
a plunger is pressed to the syringe in use to mix the two components
separated in the syringe.
[0005]
Patent Literature 2 discloses a system configured to mix
drugs by using an infusion-needle connector (container unit)
capable of attaching two drug containers in parallel.
[0006]
Although this mixing system employs the infusion-needle
connector (container unit) capable of attaching two drug
SF-2655
3
containers, since liquid is serially flown, transferring the whole
liquid consumes much time.
Citation List
Patent Literature
[0007]
Patent Literature 1: JP-A-07-136264
Patent Literature 2: JP-A-2009-534144
Summary of Invention
Problems to be Solved by the Invention
[0008]
The present invention has been made in consideration of such
circumstances, and an object of the present invention is to provide
a three-component mixing apparatus and a three-component mixing
adhesive kit that allow anyone to easily and uniformly mix three
kinds of drugs in a short period of time at the time of mixing
a three-component adhesive used in, for example, surgical
procedure (or treatment) or dental procedure (or treatment).
Means for Solving the Problems
[0009]
The present invention has been made in order to solve the
above-described problem.
SF-2655
4
A three-component mixing apparatus in accordance with the
present invention comprises:
a syringe in which a discharge opening is formed on a leading
end part and which has been filled with a first drug;
a plunger configured to be inserted into the syringe and
in which a seal member is mounted; and
an infusion-needle connector having a lead end part and a
base end part, the lead end part including a connecting part for
a second drug container filled with a second drug and a connecting
part for a third drug container filled with a third drug, the base
end part including a confluent path,
wherein the apparatus is configured to mix the first drug,
the second drug and the third drug in the syringe by attaching
the second drug container to the connecting part for the second
drug container, attaching the third drug container to the
connecting part for the third drug container, and attaching the
discharge opening of the syringe in a removable manner to the
confluent path of the base end part of the infusion-needle
connector; and then pulling the plunger against the syringe to
introduce the second drug of the second drug container and the
third drug of the third drug container into the syringe via the
infusion-needle connector.
[0010]
By the above configuration, three drugs can be mixed by
SF-2655
5
pulling the plunger one time. Consequently, mixing operation can
be easily performed in a short time.
[0011]
In the three-component mixing apparatus in accordance with
5 the present invention, it is preferable that a lubricant agent
is applied on inner periphery of the syringe.
[0012]
In the three-component mixing apparatus in accordance with
the present invention moreover, it is preferable that a lubricant
10 agent is applied on the seal member.
[0013]
The lubricant agent is a substance that is applied on inner
periphery of the syringe or on circumference of the seal member
to improve slidability of the syringe and the seal member.
15 [0014]
Examples of the lubricant agent are as follows.
[0015]
Almond oil, esterified corn oil, epoxidized soybean oil,
haze heating oil, olive oil, oleic acid, cacao butter, cacao powder,
20 beef fat, beef fat hydrogenated oil, sesame oil, wheat germ oil,
safflower oil, safflower oil fatty acid, labiataeoil, citronellal
oil, snake oil, refined rice oil, soybean hydrogenated oil,
soybean oil, soybean oil unsaponif iable matter, soybean lecithin,
zinc oil, camellia oil, corn oil, No.1-kerosene, kerosene, lard,
SF-2655
6
canola oil, castor oil, sunflower seed oil, process oil, machine
oil, mink oil, cotton seed oil, a mixture of cotton seed oil and
soybean oil, coconut oil, arachis oil, egg yolk oil, rose oil,
a copolymer solution of 2-ethylhexyl acrylate, 2-ethylhexy
5 methacrylate, and dodecyl methacrylate, a copolymer resin
emulsion of methyl acrylate and 2-ethylhexyl acrylate, an acrylic
resin alkanolamine solution, di-isobutyl adipate, di-isopropyl
adipate, a mixture of calcium alkyl allyl sulfonate and
polyoxyethylene laurylether, alkyl allyl polyether alcohol, an
10 alkyl sodium naphthalene sulfonate solution, a mixed emulsifier
of alkylbenzene sulfonate and alkyl naphthalene sulfonate, a mixed
emulsifier of alkylbenzene sulfonate, alkyl naphthalene
sulfonate, and polyoxyethylene alkyl phenyl ether, an
alkylbenzene sulfonate type emulsifier, alkylbenzene sulfonate
15 powder, a mixed emulsifier of alkylbenzene sulfonate and
polyoxyethylene alkyl ether, a mixed emulsifier of alkylbenzene
sulfonate, polyoxyethylene alkyl ether, and fatty acid
polyoxyethylene sorbitan, a mixed emulsifier of alkylbenzene
sulfonate, polyoxyethylene alkyl ether, and polyoxyethylene
20 alkyl phenyl ether, a mixed emulsifier of alkylbenzene sulfonate
and polyoxyethylene alkylphenyl ether, a mixed emulsifier of
alkylbenzene sulfonate and polyoxyethylene polycyclic phenyl
ether, a mixed emulsifier of alkylbenzene sulfonate,
polyoxyethylene alkyl phenyl ether, and polyoxyethylene alkyl
SF-2655
7
allyl ether, a mixed emulsifier of alkylbenzene sulfonate and
polyoxyethylene castor oil, alpha thioglycerin, a polymeric
dibutyl phthalate solution of 4,4'-isopropylidene diphenol and
l-chloro-2,3-epoxypropane, isobornyl thio cyanoacetate, liquid
5 lanolin, ethylene glycol, ethylene glycol ethyl ether, ethylene
glycol monobutyl ether, ethylene glycol monomethyl ether, epoxy
hexahydrophthalic diester, octyl phenoxy ethoxyethyl ether
sodium sulfonate, guar gum, glycerin, glycerin fatty acid ester,
gluconic acid, hydrogenated oil, synthetic scwaran, high glucose
10 glutinous starch syrup, N-cocoyl-L-arginine ethyl
esterDL-pyrrolidone carboxylic acid,
N-cocoyl-N-methylaminoethyl sodium sulfonate, collodion, acidic
phosphate isopropyl ester, diethanolamine, dipropylene glycol,
sucrose fatty acid ester, silicon oil, silicone resin emulsion,
15 a silicon antifoaming agent, hydrogenated vegetable oil,
hydrogenated soybean phospholipid, scwaran, scwaren, refined
soybean oil, refined honey, diisopropyl sebacate, sorbitan fatty
acid ester, low substitution degree hydroxypropylcellulose,
tocopherol, d-5-tocopherol, triacetin, glycerin triiso octanoate,
20 triethanolamine, a triethanolamine phosphate ester sodium
solution, triethylene glycol, sorbitan trioleate,
polyoxyethylene sorbitan trioleate (20E„O„), a mixture of
tri(caprylic capric acid) glyceride and glyceride tristearate,
tri(caprylic capric acid) glycerin, tris(nonylphenyl)phosphite,
SF-2655
8
concentrated benzalkonium chloride solution 50, concentrated
glycerin, honey, sodium hyaluronate, hydroxyethyl cellulose,
hydroxyethyl methyl cellulose, N-hydroxyethyllactamide solution,
hydroxylpropyl starch, hydroxylpropyl cellulose, hydroxylpropyl
5 methyl cellulose 2208, hydroxylpropyl methyl cellulose 2906,
hydroxylpropyl methyl cellulose 2910, hydroxylpropyl methyl
cellulose acetate succinate, a mixture of hydroxylpropyl methyl
cellulose 2910, titanium oxide, and macrogol 400, hydroxylpropyl
methyl cellulose phthalate, piperonyl butoxide, phytic acid,
10 diethyl phthalate, dioctyl phthalate, dibutyl phthalate,
dimethyl phthalate, butyl phthalyl butyl glycolate, 1,3-butylene
glycol, propylene glycol, propylene glycol fatty acid ester,
1,2,6-hexane triol, benzyl alcohol, polyacrylic acid,
polyacrylic acid aqueous solution (20%), sodium polyacrylate, a
15 polyacrylic acid partially neutralizing material,
polyoxyethylene hydrogenated castor oil, polyoxyethylene
hydrogenated castor oil 10, polyoxyethylene hydrogenated castor
oil 100, polyoxyethylene hydrogenated castor oil 20,
polyoxyethylene hydrogenated castor oil 40, polyoxyethylene
20 hydrogenated castor oil 5, polyoxyethylene hydrogenated castor
oil 50, polyoxyethylene hydrogenated castor oil 60,
polyoxyethylene distyryl phenyl ether, polyoxyethylene sorbitan
monolaurate, polyoxyethylene polycyclic phenyl ether ammonium
sulfate acid, polyoxyethylene castor oil, polyoxyethylene (20)
SF-2655
9
polyoxy propylene (20) glycol, polyoxyethylene (3) polyoxy
propylene (17) glycol, polyoxyethylene coconut oil fatty acid
glyceryl (7E.O.), polyoxyl 35 castor oil, polysorbate 20,
polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80,
5 polyvinyl alcohol (a partially saponifiable matter) , a mixture
of polyvinyl alcohol and diethylene glycol, a mixture of polyvinyl
alcohol and dibutyl ether, polybutene, polypropylene glycol 2000,
terminal hydroxyl substituted methyl polysiloxane silicone resin
copolymer, myristic acid, isopropyl myristate, octyldodecyl
10 myristate, lauryl methacrylate, a-monoisostearyl glyceryl ether,
monoethanolamine, sorbitan monolaurate, polyethylene glycol
monolaurate, lauryl diaminoethylglycine sodium solution, deca
glyceryl laurate, a mixture of sulfated castor oil potassium salt
and alkylbenzene sulfonate, fluid coumarone resin,
15 polyoxyethylene oleyl ether phosphate (8MOL), royal j elly,
copolymer dispersed liquid of ethyl acrylate and methyl
methacrylate, isostearyl alcohol, isostearyl palmitate,
isostearic acid, hexadecyl isostearate, octachloro dipropyl
ether, octyl decyl triglyceride, octyl dodecanol, oleyl alcohol,
20 ethyl oleate, oleyl oleate, decyl oleate, sodium oleate, xanthane
gum, hydroxypropylcellulose including light anhydrous silicic
acid, crystalline cellulose, crystalline cellulose carmellose
sodium, crystalline cellulose (fine particle), crystalline
cellulose (particle), a higher alcohol sulfated matter, a higher
SF-2655
10
fatty acid salt type emulsifying agent, a mixed emulsifying agent
of higher fatty acid salt and sulfated castor oil, synthetic
aluminum silicate, hydroxypropyl starch, crystalline cellulose,
highly refined egg yolk lecithin, wheat flour, wheat starch, wheat
5 germ powder, rice powder, rice starch, white beeswax, ethylene
glycol salicylate, starch oxide, diethylene glycol, diethylene
glycol monobutyl ether, diethylene glycol monomethyl ether,
dioctyl sodium sulfosuccinate, a-cyclodextrin, [3-cyclodextrin,
polyethylene glycol distearate, refined soybean lecithin,
10 refined egg yolk lecithin, dextran, dextran 40, dextran 70,
dextrin, palmitic acid, copolymer of n-butyl methacrylate and
n-butyl acrylate, methacrylic acid copolymer L, methacrylic acid
copolymerLD, methacrylic acid copolymer S, a mixed emulsifying
agent of glycerin monoleate, glycerin dioleate, and propylene
15 glycol, sorbitan monoleate, polyoxyethylene sorbitan monoleate
(6E.O.), coconut oil fatty acid diethanolamide, lauryl alcohol,
isopropyl linoleate, ethyl linoleate, acetyl glycerin fatty acid
ester, isoparaffin, privet wax, castor wax, adsorptive purified
lanolin, light liquid paraffin, whale wax, synthetic wax, hard
20 wax, self-emulsification type propylene glycol stearate,
self-emulsification type glyceryl monostearate, hydrogenated
lanolin alcohol, stearyl alcohol, a mixture of stearyl alcohol
and polyoxyethylene stearyl ether, stearic acid, zinc stearate,
aluminum stearate, potassium stearate, calcium stearate, sodium
SF-2655
11
stearate, poiyoxyl 40 stearate, polyoxyl 45 stearate, polyoxyl
55 stearate, magnesium stearate, a mixed wax of refined paraffin
and a carnauba wax, a refined montan wax, cetanol, a mixed wax
of cetanol and polyoxyethylene cetyl ether, a mixed wax of cetanol,
5 polyoxyethylene cetyl ether, and sodium lauryl sulfate, a mixed
wax of cetanol and polysorbate 60, a mixed wax of cetanol and
polyethylene glycol monostearate, a mixed wax of cetanol and
polyoxyethylene sorbitan monostearate, cetostearyl alcohol, a
mixture of cetostearyl alcohol and sodium cetostearyl sulfate,
10 a mixture of cetostearyl alcohol and sodium lauryl sulfate,
cetomacrogol 1000, polyoxyethylene glyceryl triisostearate,
sorbitan tristearate, polyoxyethylene sorbitan tristearate,
paraffin, a mixture of polyoxyethylene arachyl ether and stearyl
alcohol, polyoxyethylene stearylether, polyoxyethylene stearyl
15 ether phosphoric acid, polyoxyethylene cetyl ether,
polyoxyethylene cetyl ether sodium phosphate, polyoxyethylene
cetyl ether sodium phosphate (5E.O.), polyoxyethylene sorbit
beeswax, polyoxyethylene nonylphenyl ether, a mixture of
polyoxyethylene nonylphenyl ether and calcium alkylbenzene
20 sulfonate, polyoxyethylene behenyl ether, polyoxyethylene (105)
polyoxy propylene (5) glycol, polyoxyethylene (120) polyoxy
propylene (40) glycol, polyoxyethylene (160) polyoxy propylene
(30) glycol, polyoxyethylene (196) polyoxy propylene (67) glycol,
polyoxyethylene (200) polyoxy propylene glycol (70),
SF-2655
12
polyoxyethylene
polyoxyethylene
polyoxyethylene
polyoxyethylene
5 polyoxyethylene
(1)
(10)
(17)
(20)
(20)
polyoxy
polyoxy
polyoxy
polyoxy
polyoxy
propylene
propylene
propylene
propylene
propylene
(1)
(4)
(23)
(4)
(8)
cetyl
cetyl
cetyl
cetyl
cetyl
ether,
ether,
ether,
ether,
ether,
polyoxyethylene lanolin, macrogol 1000, macrogol 1500, macrogol
1540, macrogol 200, macrogol 20000, macrogol 300, macrogol 35000,
macrogol 400, macrogol 4000, macrogol 600, macrogol 6000, beeswax,
cetyl myristate, myristyl myristate, methyl myristate, Japan wax,
10 polyethylene glycol monoleate, aluminum monostearate, ethylene
glycol monostearate, glycerin monostearate, sorbitan
.monostearate, batyl monostearate, propylene glycol monostearate,
polyethylene glycol monostearate, sorbitan nomopalmitate,
glycerin monomyristate, polyoxyethylene sorbit monolaurate,
15 coconut oil fatty acid, a mixture of sodium lauryl phosphate and
glycerin monostearate, diethanolamide laurate, lauro macrogol,
lanolin alcohol, lanolin fatty acid isopropyl, liquid paraffin,
yellow petrolatum, hydrous lanolin, water adsorbable ointment
(described with any one of A and B) , hydrophilic ointment
20 (described with any one of A and B) , hydrophilic petrolatum
(described with any one of A and B), lipophilic type glycerin
monoleate, purified lanolin, simple ointment (described with any
one of A and B) , polyoxyethylene sorbit tetraoleate, white
ointment (described with any one of A and B) , white petrolatum,
SF-2655
13
cetyl palmitate, polyoxyethylene alkyl ether, polyoxyethylene
octylphenyl ether, polyoxyethylene oleylamine, polyoxyethylene
oleyl ether, polyoxyethylene oleyl ether diethanolamine
phosphate, polyoxyethylene oleyl ether sodium phosphate,
5 polyoxyethylene (42) polyoxy propylene {67} glycol,
polyoxyethylene (54) polyoxy propylene (39) glycol,
polyoxyethylene lanolin alcohol ether (5E.0.)? Macrogol ointment,
glycerin monoleate, polyoxyethylene glycerin monostearate,
polyoxyethylene sorbitan monostearate (6E.0.)r polyoxyethylene
10 laurylether sodium phosphate, petrolatum, a mixture of petrolatum
and lanolin alcohol, a mixture of petrolatum, lanolin, and lanolin
alcohol, starch acrylate 1000, starch acrylate 300, amylopectin,
candy powder, pregelatinized starch, liquid sugar syrup, ethyl
cellulose, ethyl cellulose aqueous dispersion, 2-cetyl
15 ethylhexanoate, 2-etyl-l,3-hexanediol, carrageenan, caramel,
karaya gum powder, carboxy vinyl polymer, carboxymethyl ethyl
cellulose, carboxymethyl starch sodium, carmellose, carmellose
potassium, carmellose calcium, carmellose sodium, reduced starch
syrup, reduced maltose starch syrup, high fructose liquid sugar
20 syrup, simple syrup, starch (soluble), starch ester sodium
phosphate, potato starch, semi digestion starch, glucose fructose
liquid sugar syrup, powder sugar, powder starch syrup, powder
reduced maltose starch syrup, powder cellulose, pectin, starch
syrup, and methyl cellulose.
SF-2655
14
[0016]
The lubricant agent preferred is the one which is dissolved
in either or both of the second drug and the third drug to reduce
slidability of the seal member.
5 [0017]
By the lubricant agent being dissolved in either or both
of the second drug and the third drug after attaching the second
drug container and the third drug container to the infusion-needle
connector that has been attached to the syringe and then pulling
10 the plunger to introduce the second drug and the third drug through
the infusion-needle connector into the syringe, slidability of
the seal member is reduced so that the plunger does not return
to its original position even when the inside of the syringe is
at a negative pressure state.
15 [0018]
From such advantageous effects, the lubricant agents
mentioned above are preferable examples. In particular, silicon
oil can be mentioned as a more preferable example.
[0019]
20 By using silicon oil as the lubricant agent, pulling the
plunger in order to carry out the three-component mixing allows
part of the silicon oil as the lubricant agent to be dissolved
by drugs that come to be introduced into the syringe, resulting
in the decrease of slidability of the plunger,
SF-2655
15
[0020]
By the above configuration, suction force from the discharge
opening side to be applied to the plunger would not cause the
plunger to return to its original position. Consequently, the
5 plunger can be stopped on its current position even when a hand
is released from the plunger.
[0021]
When silicon oil is applied as described above, pulling the
plunger in order to carry out the three-component mixing allows
10 part of the silicon oil to be dissolved by drugs that come to be
introduced into the syringe. Meanwhile, silicon oil remaining
on inner periphery of the syringe and the seal member as well as
silicon oil on the side face of the seal member that has not come
into contact with drugs introduced into the syringe keep enabling
15 the plunger to be operated easily.
[0022]
In the present invention, it is preferable that the
connecting part for the second drug container and the connecting
part for the third drug container, which are formed on the
20 inf usion-needle connector, are each provided with a needle member.
[0023]
By the above configuration, attaching the second drug
container and the third drug container to the connecting parts
of the infusion-needle connector can be accompanied by forming
SF-2655
16
holes on the drug containers.
[0024]
In the present invention, it is preferable that the first
drug is powder, the second drug is a liquid, and the third drug
5 is a liquid.
[0025]
By the above configuration where the first drug is powder,
the second drug is a liquid and the third drug is a liquid, a user
can mix and use the three components immediately.
10 [0026]
A three-component mixing adhesive kit in accordance with
the present invention comprises the three-component mixing
apparatus as defined in any one of the above descriptions
disassembled in a container box,
15 [0027]
The above configuration is convenient for shipment,
management and carrying around of the three-component mixing
adhesive kit and for allowing a user to mix and use the three
components immediately without making mistakes.
20
Advantageous Effects of Invention
[0028]
By the three-component mixing apparatus in accordance with
the present invention, three drugs can be mixed by one-time
SF-2655
17
operation of pulling the plunger, so that three drugs in an
appropriate amount can be easily and uniformly mixed with each
other in a short time by anyone.
[0029]
5 Furthermore, application of silicon oil on inner periphery
of the syringe and the seal member, wherein the silicon oil as
a lubricant agent is dissolved by drugs introduced into the syringe,
reduces slidability cf the plunger, so that the plunger can be
prevented from returning to its original position even when a hand
10 is released from the plunger during pulling the plunger. This
configuration allows for easy stirring without the need for
cumbersome operations such as stirring while holding the plunger.
[0030]
Furthermore, when the infusion-needle connector is provided
15 with needle members, attaching the drug containers can be
accompanied by forming holes on the drug containers.
[0031]
Furthermore, when the first drug is powder, the second drug
is a liquid and the third drug is a liquid, the drugs can be
20 effectively used for mixing of a surgical adhesive agent, a dental
adhesive agent and so on. Consequently, a user such as a surgeon
and a dentist, when needing an adhesive agent for a procedure or
a treatment, can immediately mix and use three components as an
adhesive agent on site.
SF-2655
18
[0032]
Furthermore, by using a three-component mixing adhesive kit
in accordance with the present invention, anyone can easily carry
out a mixing operation without making mistakes.
5
Brief Description of the Drawings
[0033]
[Fig- 1]
Fig. 1 is an exploded view showing an attaching mode when
10 a three-component mixing apparatus and two drug containers in
accordance with an embodiment of the present invention are
attached to each other.
[Fig. 2]
Fig. 2 is a schematic cross-sectional view showing a
15 relationship between a three-component mixing apparatus in
accordance with an embodiment of the present invention and a
sealing member and a brush member that are selectively attached
to the three-component mixing apparatus.
[Fig. 3]
20 Fig. 3 is a perspective view showing an infusion-needle
connector that is adopted for the three-component mixing apparatus
in accordance with an embodiment of the present invention and a
drug container that is attached to the infusion-needle connector.
[Fig. 4]
SF-2655
19
Fig. 4 is a cross-sectional view showing an infusion-needle
connector shown in Fig. 3.
[Fig. 5]
Fig. 5 is a partially disassembled cross-sectional view
5 showing separately a container body and a cap body of the drug
container shown in Fig. 3.
[Fig. 6]
Fig. 6 is a perspective view showing a three-component
mixing adhesive kit in which each member of the three-component
10 mixing apparatus in accordance with an embodiment of the present
invention is contained in a container box.
[Fig. 7]
Fig. 7 is a schematic cross-sectional view showing a state
of the three-component mixing apparatus in accordance with an
15 embodiment of the present invention before a mixing operation is
carried out.
[Fig. 8]
Fig. 8 is a perspective view showing a modified example of
an infusion-needle connector.
20 [Fig. 9]
Fig. 9 is a cross-sectional view showing a state in which
a drug container is attached to the infusion-needle connector
shown in Fig, 8.
[Fig. 10]
SF-2655
20
Figs. 10(A) and 10(B) are explanatory drawings showing
another modified example of an infusion-needle connector and are
explanatory drawings when a cylindrical member of the
infusion-needle connector is extended and the two drug containers
5 are attached to the infusion-needle connector by using a
protrusion on inner periphery of the extended part.
[Fig. 11]
Fig. 11 is an explanatory drawing when the two drug
containers are attached to the infusion-needle connector by using
10 a cap made of elastomer.
[Fig. 12]
Fig. 12 is an explanatory drawing when the two drug
containers are attached to the infusion-needle connector by using
a collecting body.
15 [Fig. 13]
Fig. 13 is a compendium showing examples of a variety of
the brush member shown in Fig. 2.
[Fig. 14]
Fig. 14 is a perspective view showing a nozzle in a pipe
20 shape as substitute for the brush member shown in Fig. 13.
Description of Embodiments
[0034]
A three-component mixing apparatus in accordance with an
SF-2655
21
embodiment of the present invention will be described below in
detail with reference to the drawings.
[0035]
Fig. 1 is an exploded view showing an attaching mode when
5 a three-component mixing apparatus and two drug containers in
accordance with an embodiment of the present invention are
attached to each other. Such a three-component mixing apparatus
2 are employable to a wide variety of use applications as an
apparatus configured to mix three components. In the following
10 descriptions, however, an example that is applied to the mixing
of an adhesive agent composed of three components will be
described.
[0036]
The three-component mixing apparatus 2 in accordance with
15 the embodiment shown in Fig. 1 is provided with a syringe 4 in
a cylindrical shape in which a first drug A is introduced in
advance; a plunger 8 configured to be inserted into the syringe
4 and in which a seal member 6 is mounted on the leading end part;
and an infusion-needle connector 10 that is attached to the outside
20 of a discharge opening 4a of the syringe 4 in a removable manner.
As described later, a second drug container 16 and a third drug
container 18 are attached to the three-component mixing apparatus
2.
[0037]
SF-2655
22
When the syringe 4 is filled with the first drug A, a sealing
member 12 shown in Fig. 2 is attached to the discharge opening
4a of the syringe 4 in a removable manner. This configuration
can prevent a drug or the like from leaking to the outside of the
5 syringe 4. Consequently, it is preferable that the sealing member
12 is used from shipment until an operation of mixing drugs is
carried out for instance. In Fig, 1, a symbol 4b is a plug part
and a symbol 4c is an inner screw.
[0038]
10 On the other hand, after three components are mixed by the
three-component mixing apparatus 2 in a mode described later, when
drugs that have been mixed are taken out as an adhesive agent,
a brush member 14 shown in Fig. 2 is attached in place of the sealing
member 12. In contrast to the sealing member 12, since the brush
15 member 14 is internally provided with a path that leads up to the
outside, the brush member 14 enables an adhesive agent to be
applied or discharged.
[0039]
In general, it is preferable that the plunger 8 is made of
20 a polypropylene resin, although it varies depending on the type
of a drug that configures an adhesive agent. Although not
restricted in particular, it is preferable that the seal member
6 is made of a butyl-based rubber that is provided with chemical
resistance (for instance, a butyl rubber and a chlorinated butyl
SF-2655
23
rubber) . Moreover,, it is preferable that the seal member 6 is
coated with silicon oil.
[0040]
A connecting part 20 configured to attach a second drug
5 container 16 and a connecting part 22 configured to attach a third
drug container 18 are formed in parallel on the leading end part
of the infusion-needle connector 10. On the other hand, a
confluent path 30 is formed on a base end part of the
infusion-needle connector 10. That is to say, in the
10 infusion-needle connector 10 as shown in Fig. 4, two paths 26a
and 28a are formed on one side, one confluent path 30 is formed
on the other side, and the paths 26a and 28a and the confluent
path 30 are connected to each other through bypass paths 26b and
28b.
15 [0041]
As shown in Fig. 3, the connecting part 20 and the connecting
part 22 that are formed in parallel in the infusion-needle
connector 10 are provided with cylindrical skirt members 25 and
25 that have been halved by a slit 24 in a linear shape. This
20 configuration enables the skirt members 25 to be slightly opened
in an enlarged manner in a radial direction.
[0042]
On the other hand, needle members 26 and 28 are protruded
on the central part of the connecting part 20 and the connecting
SF-2655
24
part 22 that are provided with the cylindrical skirt member 25,
in which a through hole 34 is formed in the leading end part of
the needle members 26 and 28.
[0043]
5 It is preferable that the second drug container 16 and the
third drug container 18 that are attached to the infusion-needle
connector 10 in a removable manner have the same shape, whereby
the same materials can be used for the two containers.
[0044]
10 Since the second drug container 16 and the third drug
container 18 have the same shape, the second drug container 16
will be described as an example in the following with reference
to Fig. 5.
[0045]
15 As shown in Fig. 5, the second drug container 16 is
configured by a container body 16a and a cap body 32 . In particular,
it is preferable that the container body 16a is made of a glass
with chemical resistance.
[0046]
20 On the other hand, in the cap body 32 made of an appropriate
synthetic resin, an aperture 32b is formed at the central part
of a top board part 32a and a flange part 32c the diameter of which
is slightly larger is formed on the lower end part. Since such
a flange part 32c is formed on the lower end part of the cap body
SF-2655
25
32, when the second drug container 16 is inserted into the
connecting part 20 of the infusion-needle connector 10, the
cylindrical skirt member 25 is enlarged and opened.
[0047]
5 Consequently, when the second drug container 16 with the
cap body 32 mounted to the container body 16a is inserted into
the connecting part 20 of the infusion-needle connector 10, and
the flange part 32c of the cap body 32 passes through an aperture
end of the connecting part 20, the cylindrical skirt member 25
10 is slightly enlarged and opened and captures the flange part 32c.
Moreover, since restoring force to make the cylindrical skirt
member 25 return to its original position is applied, the second
drug container 16 can be held with certainty by the restoring
force.
15 [0048]
On the other hand as shown in Fig. 5, a seal member 37 is
mounted on the reverse side of the top board part 32a of the cap
body 32 in such a manner that the aperture 32b is covered.
[0049]
20 The seal member 37 is provided with a three-layer structure.
More specifically, the sealing member 37 is provided with a core
material 37a made of a rubber member, more preferably a butyl-based
rubber with high chemical resistance (for instance, a butyl rubber
and a chlorinated butyl rubber), in the central part, and a
SF-2655
26
fluorine resin film 37b such as Teflon (registered trademark) is
bonded on the both sides of the core material 37a.
[0050]
After the container bodies 16a, corresponding to the second
5 drug container 16 and the third drug container 18, are filled with
the second drug B and the third drug C, it is preferable that the
entire outer periphery of the container body 16a and the cap body
32 (excluding the aperture 32b of the cap body 32) is covered with
a shrink film.
10 [0051]
When the entire outer periphery of the container body 16a
and the cap body 32 is covered with a shrink film as described
above, an inadvertent rotation of the cap body 32 can be prevented.
This configuration can prevent the second drug B and the third
15 drug C introduced inside from leaking outside.
[0052]
As shown in Fig. 5, the second drug container 16 is attached
to the connecting part 20 of the infusion-needle connector 10 in
a removable manner and the third drug container 18 is attached
20 to the connecting part 22 of the infusion-needle connector 10 in
a removable manner. At this time, the needle members 26 and 28
protruded inside the infusion-needle connector 10 stick the seal
member 37 of the second drug container 16 and the seal member 37
of the third drug container 18, respectively. At this time, holes
SF-2655
27
each are opened in the seal members 37 and 37 . Thereby, the second
drug B and the third drug C in the container body 16a can be
discharged outward.
[0053]
5 The constituent elements of the three-component mixing
apparatus in accordance with an embodiment of the present
invention are formed as described above. It is preferable that
the above constituent elements are packed in a container box 38
in an appropriate state as shown in Fig. 6 and are configured as
10 a three-component mixing adhesive kit 50 and the three-component
mixing adhesive kit 50 is shipped or managed in this state.
[0054]
More specifically, the syringe 4 is filled with the first
drug A, the plunger 8 is inserted into the syringe 4, and the
15 sealing member 12 is attached to the discharge opening 4a of the
syringe 4. As described above, a syringe assembly body 41 is
configured by the syringe 4, the plunger 8 and the sealing member
12. In addition to the syringe assembly body 41, the second drug
container 16 filled with the second drug B, the third drug
20 container 18 filled with the third drug C, the infusion-needle
connector 10 and the brush member 14 are packed in the container
box 38.
[0055]
After each of the constituent elements is packed in the
SF-2655
28
container box 38 as described above, a sterilizing paper 42 is
sealed on the upper opening of the container box 38 for shipment.
[0056]
When the three-component mixing apparatus 2 is used for the
5 mixing of an adhesive agent in surgical procedure (or treatment)
or dental procedure (or treatment), the first drug A is a polymer
(powder) , the second drug B is a catalyst (liquid) , and the third
drug C is a monomer (liquid) . In this case, as a polymer (powder)
that is the first drug A, there can be mentioned for instance a
10 powder made of a methacrylate polymer and a powder made of an
acrylate polymer.
[0057]
As a catalyst (liquid) that is the second drug B, there can
be mentioned for instance an organic boron compound that is
15 typified by trialkyl boron or the partial oxide thereof and a
liquid in which an organic boron compound is dissolved in a solvent
such as an aprotic solvent and a mixed solvent in which a small
amount of alcohol is mixed to an aprotic solvent. As a monomer
(liquid) that is the third drug C, there can be mentioned for
20 instance methacrylate and acrylate that are typified by methyl
methacrylate, ethyl methacrylate, butyl methacrylate,
2-hydroxyethyl methacrylate, 3-(trimethoxysilyl)propyl
methacrylate, 2-(phenyl phosphoryl)ethyl methacrylate,
2-hydroxy-3- ((3-naphthoxy) propyl methacrylate,
SF-2655
29
N-phenyl-N-(2-hydroxy-3-methacryroxy)propyl glycine, ethylene
glycol dimethacrylate, diethylene glycol dimethacrylate,
triethylene glycol dimethacrylate, 1,4-butanediol
dimethacrylate, 1,3-butanediol dimethacrylate,
5 2,2-bis[4-(2-hydroxy-3-methacryroxypropoxy)phenyl]propane,
2,2-bis(4-methacryroxyphenyl)propane,
2,2-bis(4-methacryroxyethoxyphenyl)propane,
2,2-bis(4-methacryroxypolyethoxyphenyl)propane,
di(methacryroxyethyl)trimethylhexamethylene diurethane,
10 trimethylolpropane trimethacrylate, hydroxylnaphthoxypropyl
methacrylate, 4-methacryroxyethyl trimellitic anhydride,
4-methacryroxyethyl trimellitic acid,
11-methacryroxy-l, 1-undecane dicarboxylic acid, 10-methacryroxy
decamethylene phosphate, 4-methaacryloyl aminosalicylic acid,
15 and 5-methaacryloyl aminosalicylic acid.
[0058]
The usage when three components are mixed will be described
next „
[0059]
20 The syringe assembly body 41, the second drug container 16,
the third drug container 18, and the infusion-needle connector
10 are taken out from the container box 38 for instance. First,
the sealing member 12 is detached from the syringe assembly body
41. Then, the infusion-needle connector 10 is attached to the
SF-2655
30
syringe assembly body 41, and the second drug container 16 and
the third drug container 18 are then attached to the
infusion-needle connector 10.
[0060]
5 Through the above steps, the mixing of three components is
ready as shown in Fig. 7.
[0061]
In the meanwhile, it is also possible that the second drug
container 16 and the third drug container 18 are attached to the
10 infusion-needle connector 10 first and the infusion-needle
connector 10 to which the second drug container 16 and the third
drug container 18 have been attached is then attached to the
syringe assembly body 41 from which the sealing member 12 has been
detached.
15 [0062]
As shown in Fig. 7, the plunger 8 is pulled down from the
syringe 4 with the second drug container 16 and the third drug
container 18 positioned on the upper side.
[0063]
20 While an operation of pulling down of the plunger 8 from
the syringe 4 is being carried out as described above, the second
drug B in the second drug container 16 and the third drug C in
the third drug container 18 can be sucked into the confluent path
30 through the bypass paths 26b and 28b, and can be introduced
SF-2655
31
into the syringe 4.
[0064]
The mixed drug of the second drug B and the third drug C
that have been introduced into the syringe 4 is converged with
5 the first drug A in the syringe 4. Even when a hand is released
from the plunger 8 during the above operation, the plunger 8 does
not return to its original position. This is because slidability
of the plunger 8 is reduced as a result of part of the silicon
oil applied on inner periphery of the syringe 4 and part of the
10 silicon oil applied on the seal member 6 being dissolved in the
second drug B and the third drug C introduced into the syringe
4.
[0065]
When the second drug B and the third drug C are converged
15 with the first drug A in the syringe 4 as described above, a kit
assembly body 40 to which the infusion-needle connector 10 has
been attached is shaken up and down in a hand in order to stir
the drugs to rapidly complete uniform mixing.
[0066]
20 When the mixing is completed, the infusion-needle connector
10 is detached and the brush member 14 shown in Fig. 2 is attached
in place of the infusion-needle connector 10, whereby a
preparation before use is completed.
[0067]
SF-2655
32
After this preparation is completed, pushing the plunger
8 toward the discharge opening 4a can cause an adhesive agent
desired to be discharged from the brush member 14 in appropriate
amount. This enables applying the adhesive agent to, for example,
5 surgical procedure (or treatment) or dental procedure (or
treatment).
[0068]
After use, the apparatus is put and collected into a
container designed for waste disposal or the like and then
10 discarded.
[0069]
The three-component mixing apparatus 2 in accordance with
an embodiment of the present invention can be effectively applied
to the mixing of adhesive agents that would be hardened if the
15 mixing of three components were not rapidly carried out. In
addition, the operation is simple enough for anyone to carry out
the operation without making mistakes.
[0070]
When a large quantity of adhesive agent is used, using a
20 plurality of three-component mixing apparatuses 2 or increasing
a capacity of the syringe 4, the second drug container 16 and the
third drug container 18 can provide specified quantity.
[0071]
While the three-component mixing apparatus 2 in accordance
SF-2655
33
with an embodiment of the present invention has been described
above, the present invention is not restricted to the embodiment
described above.
[0072]
5 For instance, the infusion-needle connector 10 shown in Figs.
3 and 4 may have other shapes. For example, in an infusion-needle
connector 60 shown in Fig. 8, a wall body of the connecting part
20 and that of the connecting part 22 are formed in an integrated
manner; the wall body is extended while having the same size to
10 the outside of the confluent path 30; and protruding streaks 61,
61 and 61 for the frictional resistance are formed on the outer
periphery of a cylindrical member 62 extended as described above.
[0073]
In an infusion-needle connector 60 shown in Fig. 8, a
15 plurality of protrusions 64 (three protrusions in Fig. 8) are
formed on inner periphery of the connecting part 20 and the
connecting part 22 separately at a predetermined interval.
[0074]
The infusion-needle connector 60 configured as described
20 above has a large area which contacts with a hand, and thus can
be easily grasped by a user, which facilitates attaching of the
drug containers and the stirring operation.
[0075]
When a plurality of protrusions 64 are formed on inner
SF-2655
34
periphery of the connecting part 20 and the connecting part 22,
the following advantageous functional effects can be obtained.
[0076]
That is to say, when the drug containers 16 and 18 are further
5 inserted to the confluent path 30 side from their position shown
in Fig. 9, moving the drug containers 16 and 18 over the protrusions
64 would require a larger pressing force compared to when the
protrusions 64 are net formed.
[0077]
10 In addition to the need for a larger pressing force, a user
can experience force varied and sound generated when the drug
containers 16 and 18 are moved over the protrusions 64 and sound
made by hitting to a bottom face, thereby confirming whether or
not the drug containers 16 and 18 have been inserted with absolute
15 certainty.
[0078]
When the drug containers 16 and 18 have been inserted with
absolute certainty as described above, the protrusion 64 enters
among a flange part 32c and the container body 16a of the drug
20 containers 16 and 18 and a shoulder part of the container body
16a, thereby preventing the drug containers 16 and 18 from dropping
out of the side of the confluent path 30.
Moreover, an infusion-needle connector 80 shown in Figs.
10(A) and 10{B) can also be adopted.
SF-2655
35
[0079]
The infusion-needle connector 80 is a modified example of
the infusion-needle connector 60 shown in Fig, 8. For the
infusion-needle connector 80, the cylindrical member 62 is further
5 extended to form a skirt part 82. In a fixing part of the drug
containers 16 and 18 in the skirt part 82, the slits 24 and 24
are formed in an axial direction. Moreover, a plurality of
protrusions 64 and 65 is formed in a circumferential direction
on inner periphery of the fixing part of the drug containers 16
10 and 18.
[0080]
By forming a plurality of protrusions 65 as well as a
plurality of protrusions 64 on inner periphery of the
infusion-needle connector 80, the protrusions 65 enter between
15 a flange part 32c and a shoulder part of the container body 16a,
so that the cap bodies 32 and 32 of the drug containers 16 and
18 can be temporarily held and contained.
[0081]
Thus, with the needle members 26 and 28 not yet inserted
20 into the drug containers 16 and 18, the drug containers 16 and
18 can be temporarily fixed to the infusion-needle connector 80.
Further inserting the drug containers 16 and 18 from their position
shown in Fig. 10 would require a larger pressing force than ever
before since the drug containers 16 and 18 are moved over the
SF-2655
36
protrusions 64.
[0082]
At the same time, the drug containers 16 and 18 are moved
beyond the needle members 26 and 28 and fixed completely to the
5 internal position, and the cap body 32 of the drug containers 16
and 18 comes into contact with the bottom face that is formed on
the internal position of the skirt part 82. A user can feel force
varied and sound generated when the drug containers 16 and 18 are
moved over the protrusions 64 as well as sound generated by hitting
10 to the bottom face, thereby confirming whether or not the drugcontainers
16 and 18 have been inserted with absolute certainty.
When the drug containers 16 and 18 have been inserted with absolute
certainty as described above, the protrusion 64 enters among the
flange part 32c and the container body 16a of the drug containers
15 16 and 18 and a shoulder part of the container body 16a, thereby
preventing the drug containers 16 and 18 from dropping out of the
infusion-needle connector 80.
[0083]
By this configuration, as shown in Fig. 6 for instance, when
20 the constituent elements are packed in the container box 38 as
the three-component mixing adhesive kit 50, it is also possible
that the second drug container 16 and the third drug container
18 are temporarily fixed to the infusion-needle connector 80 and
then shipped.
SF-2655
37
[0084]
As shown in Fig. 11, when a cap 66 made of elastomer is
prepared and the cap 66 is fitted to an aperture end of the
infusion-needle connector 60 in appressed manner, for instance,
5 the inside of the cap 66 enters between the flange part 32c and
a shoulder part of the container body 16a, thereby temporarily
fixing the drug containers 16 and 18 to the infusion-needle
connector 60 or the like.
[0085]
10 As shown in Fig. 12, when a collecting body 68 that can hold
two drug containers 16 and 18 in parallel in a removable manner
is prepared and the drug containers 16 and 18 are fixed to the
collecting body 68 in advance, the drug containers 16 and 18 can
be fixed to the infusion-needle connector 60 or the like by
15 one-time operation. A material of the collecting body 68 can be
any one of an elastomer and a synthetic resin.
[0086]
The brush member 14 shown in Fig. 2 is not restricted to
the embodiment described above.
20 [0087]
As shown in Fig. 13, for instance, when a leading end face
that forms a discharge part 35 of the brush member 14 is slanted,
an adhesive agent can be applied easily.
[0088]
SF-2655
38
In Fig. 13, the brush member 4S shows a standard form.
[0089]
On the other hand, in the brush member 4S' , the discharge
part 35 is slanted at a predetermined angle.
5 [0090]
In the brush members 41/ and 4R' , the discharge part 35 is
slanted at a predetermined angle similarly to the brush member
4S' .
[0091]
10 In the brush members 4L and 41/ , the discharge part is
slanted in such a manner that a left end part is higher than a
right end part as shown in Fig. 13. Consequently, the brush
members 4L and 41/ are suitable for being used with a left hand.
[0092]
15 In the brush members 4R and 4R', the discharge part is
slanted in such a manner that a right end part is higher than a
left end part as shown in Fig. 13= Consequently, the brush members
4R and 4R' are suitable for being used with a right hand.
[0093]
20 Selecting an inclination angle of the brush member according
to a dominant hand of a user as described above can improve the
usability of the apparatus. When a small amount of an adhesive
agent is used, a nozzle 84 with a pipe shape can also be used as
shown in Fig. 14.
SF-2655
39
Industrial Applicability
[0094]
The present invention can be preferably utilized for the
5 mixing of adhesive agents that are used in surgical procedure (or
treatment) or dental procedure (or treatment). In addition, the
present invention can also be applied to the mixing of adhesive
agents of dental materials or the mixing of adhesive agents of
industrial products.
10 [0095]
Moreover, the present invention can also be effectively
applied to the mixing of three components other than adhesive
agents. In particular, the present invention is effective when
three components are mixed in a short time.
15
Reference Signs List
[0096]
2: Three-component mixing apparatus
4: Syringe
20 4a: Discharge opening
4b: Plug part
4c: Inner screw
6: Seal member
8: Plunger
SF-2655
40
10: Infusion-needle, connector
12: Sealing member
14: Brush member
16: Second drug container
5 16a: Container body
18: Third drug container
20: Connecting part
22: Connecting part
24: Slit
10 25: Cylindrical skirt member
26: Needle member
2 6a: Path
26b: Bypass path
28: Needle member
15 28a: Path
28b: Bypass path
30: Confluent path
32: Cap body
32a: Top board part
20 32b: Aperture
32c: Flange part
34: Through hole
35: Discharge part
37 : Seal member
SF-2655
41
37a: Core material
37b: Fluorine resin film
38: Container box
40: Kit assembly body
5 41: Syringe assembly body
42: Sterilizing paper
50: Three-component mixing adhesive kit
60: Infusion-needle connector
61: Protruding streak
10 62: Cylindrical member
64: Protrusion
66: Cap
68: Collecting body
80: Infusion-needle connector
15 82: Skirt part
84: Nozzle
A: First drug
B: Second drug
C: Third drug
SF-2655
42
CLAIMS
[Claim 1]
1. A three-component mixing apparatus comprising:
a syringe in which a discharge opening is formed on a leading
end part and which has been filled with a first drug;
a plunger configured to be inserted into the syringe and
in which a seal member is mounted; and
an infusion-needle connector having a lead end part and a
base end part, the lead end part including a connecting part for
a second drug container filled with a second drug and a connecting
part for a third drug container filled with a third drug, the base
end part including a confluent path,
wherein the apparatus is configured to mix the first drug,
the second drug and the third drug in the syringe by attaching
the second drug container to the connecting part for the second
drug container, attaching the third drug container to the
connecting part for the third drug container, and attaching the
discharge opening of the syringe in a removable manner to the
confluent path of the base end part of the infusion-needle
connector; and then pulling the plunger against the syringe to
introduce the second drug of the second drug container and the
third drug of the third drug container into the syringe via the
infusion-needle connector.
SF-2655
43
[Claim 2]
2. The three-component mixing apparatus as defined in
claim 1, wherein a lubricant agent is applied on inner periphery
of the syringe.
[Claim 3]
3. The three-component mixing apparatus as defined in
claim 1, wherein a lubricant agent is applied on the seal member.
[Claim 4]
4. The three-component mixing apparatus as defined in
claim 2 or 3, wherein the lubricant agent is silicon oil.
[Claim 5]
5. The three-component mixing apparatus as defined in
any one of claims 1 to 4, wherein the connecting part for the second
drug container and the connecting part for the third drug container
that are formed on the infusion-needle connector are each provided
with a needle member.
[Claim 6]
6. The three-component mixing apparatus as defined in
any one of claims 1 to 5, wherein the first drug is powder, the
second drug is a liquid, and the third drug is a liquid.
SF-2655
44
[Claim 7]
7. A three-component mixing adhesive kit comprising the
three-component mixing apparatus as defined in any one of claims
1 to 6 disassembled in a container box.